Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 6:20 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 322 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Erbitux Clear all

Conditions: Metastatic Pancreatic Cancer
Interventions: Ixabepilone, Cetuximab; Drug
Lead sponsor: R-Pharm; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 9
States / cities: Washington D.C., District of Columbia • Jacksonville, Florida • Miami, Florida + 6 more

Conditions: Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Colorectal Tumors, Neoplasms, Colorectal
Interventions: NUC-3373 + leucovorin, NUC-3373, NUFOX, NUFOX + VEGF pathway inhibitor, NUFOX + EGFR inhibitor, NUFIRI, NUFIRI + VEGF pathway inhibitor, NUFIRI + EGFR inhibitor, NUC-3373 + bevacizumab; Drug
Lead sponsor: NuCana plc; Other
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 6
States / cities: Boston, Massachusetts • Durham, North Carolina • Nashville, Tennessee + 2 more

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Cetuximab, IMC-A12, Surgical tumor resection; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced Solid Tumours, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC)
Interventions: AZD0022, Cetuximab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Duarte, California • New York, New York • Fairfax, Virginia

Conditions: Head and Neck Cancer
Interventions: TAK-981, Cetuximab, Avelumab, TAK-981 + Cetuximab, TAK-981 + Avelumab; Drug · Biological · Combination Product
Lead sponsor: Presage Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 6
States / cities: Ann Arbor, Michigan • New York, New York • North New Hyde Park, New York + 2 more

Conditions: NSCLC
Interventions: Imprime PGG Injection, Cetuximab, Paclitaxel, Carboplatin; Biological · Drug
Lead sponsor: HiberCell, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 5
States / cities: Augusta, Georgia • Terre Haute, Indiana • Minneapolis, Minnesota + 2 more

Conditions: Squamous Cell Carcinoma of the Head and Neck
Interventions: Pazopanib, Cetuximab; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Head and Neck Neoplasms
Interventions: paclitaxel albumin-stabilized nanoparticle formulation, Cisplatin, Fluorouracil, Intensity modulated radiation therapy, Cetuximab, Quality-of-life assessment; Drug · Radiation · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Esophageal Cancer
Interventions: cetuximab, cisplatin, irinotecan hydrochloride, radiation therapy; Biological · Drug · Radiation
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 132
States / cities: Mobile, Alabama • Little Rock, Arkansas • Berkeley, California + 84 more

Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Stage IB Cervical Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage IVA Cervical Cancer
Interventions: Internal Radiation Therapy, 3-Dimensional Conformal Radiation Therapy, Cetuximab, Cisplatin; Radiation · Biological · Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 15
States / cities: Augusta, Georgia • Chicago, Illinois • Indianapolis, Indiana + 10 more

Conditions: Non-Small-Cell Lung Carcinoma
Interventions: Cetuximab + Gefitinib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: selumetinib, cetuximab, laboratory biomarker analysis, pharmacological study; Drug · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 3
States / cities: Bethesda, Maryland • Madison, Wisconsin • Milwaukee, Wisconsin

Conditions: Non-Small Cell Lung Cancer
Interventions: Gemcitabine, Cisplatin, IMC-A12 (cixutumumab), Cetuximab, Carboplatin; Drug · Biological
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 12
States / cities: Anniston, Alabama • La Jolla, California • Orange, California + 6 more

Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Interventions: Cyclophosphamide, Cetuximab; Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Previously-Irradiated, Squamous Cell Carcinoma of the Head and Neck Cancer
Interventions: SBRT, Cetuximab, Docetaxel; Radiation · Drug
Lead sponsor: Heath Skinner; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Colorectal Cancer, Colorectal Adenocarcinoma, Colorectal Cancer Metastatic, Advanced Colorectal Carcinoma, Advanced Colorectal Adenocarcinoma
Interventions: VS-6766/avutometinib, Cetuximab, Pill Diary; Drug · Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck
Interventions: Ibrutinib 560mg PO daily (Imbruvica), Cetuximab, Nivolumab; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Large Cell Lung Cancer, Malignant Pleural Effusion, Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions: docetaxel, cetuximab, bortezomib; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Miami Beach, Florida

Conditions: Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
Interventions: NKTR-255, Cetuximab; Drug
Lead sponsor: Nektar Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 6
States / cities: San Diego, California • San Francisco, California • Minneapolis, Minnesota + 3 more

Conditions: Pancreatic Cancer
Interventions: Cetuximab, Pancreatic tumor vaccine, Cyclophosphamide; Drug · Biological
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Brain Neoplasm, Malignant Glioma
Interventions: Cetuximab, Cetuximab-IRDye 800CW, Tumor resection; Biological · Drug · Procedure
Lead sponsor: Eben Rosenthal; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Advanced Colorectal Cancer
Interventions: Defactinib, Cetuximab, Avutometinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HER2 Positive Gastric Cancer, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, EGFR Positive Solid Tumor, Advanced Solid Tumors, HER2-positive Breast Cancer, Hepatocellular Carcinoma, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Pancreatic Cancer, Melanoma
Interventions: FATE-NK100, Cetuximab, Trastuzumab; Drug
Lead sponsor: Fate Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 4
States / cities: San Diego, California • Minneapolis, Minnesota • Columbus, Ohio + 1 more

Conditions: Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Glioma, Brain Neoplasm, Brain Cancer, Brain Tumor, Brain Tumor, Recurrent, Brain Neoplasm, Malignant
Interventions: Intra-arterial Cetuximab, Intra-arterial Mannitol, Hypofractionated re-irradiation; Drug · Radiation
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2036
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer

A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment

Preoperative Treatment With Cetuximab and/or IMC-A12

A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation

Intratumoral Microdosing of TAK-981 in Head and Neck Cancer

Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer

Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)

Induction Chemotherapy With ACF Followed by Chemoradiation Therapy for Adv. Head & Neck Cancer

S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer

Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer

A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors

A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before

Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer

SBRT With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated SCCHN

A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer

Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC

Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Study of NKTR 255 in Combination With Cetuximab in Solid Tumors

Vaccine Therapy, Cyclophosphamide, and Cetuximab in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer

Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery

Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors

Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA